C. Robert Cory

Health Technology

Consumer Services

Profile

Dr. C.
R.
Cory is Global Head-Business Development at biOasis Technologies, Inc. Dr. Cory was previously employed as Vice President-Business Development by MIGENIX, Inc. He received his MBA from Wilfrid Laurier University and a doctorate degree from The University of Waterloo.

Former positions of C. Robert Cory

Companies	Position	End
MIGENIX, Inc. MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.	Corporate Officer/Principal	24/03/2010
BIOASIS TECHNOLOGIES INC.	Corporate Officer/Principal	-

See the detail of C. Robert Cory's experience

Training of C. Robert Cory

The University of Waterloo	Doctorate Degree
Wilfrid Laurier University	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of C. Robert Cory's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
BIOASIS TECHNOLOGIES INC.	Health Technology

Private companies	1
MIGENIX, Inc. MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.	Health Technology